Expression of Shh, Gli1, and Cyr61 in Gastric Cancer Predicts Overall Survival of Patients: A Retrospective Study

Abstract

Objective This study aimed to evaluate the expression levels of Shh, Gli1, and Cyr61 proteins in gastric cancer tissues and analyze the relationship between these three proteins and the clinicopathological factors and prognosis of patients. Methods This was a retrospective study. Four hundred gastric cancer tissue specimens from patients who underwent radical gastrectomy in Zhangye People’s Hospital affiliated to Hexi University between February 2013 and February 2021 underwent immunohistochemical analysis. Results The positive expression rates of Shh, Gli1, and Cyr61 in gastric cancer tissues were 55.5%, 56.5%, and 64.5%, respectively. The expressions of Shh, Gli1, and Cyr61 in gastric cancer tissues were significantly correlated with tumor size, depth of invasion, and degree of differentiation (P < .05). The expression of Shh protein was positively correlated with the expression of Gli1 protein (P < .01), and the expression of Gli1 protein was positively correlated with the expression of Cyr61 protein (P < .01). Univariate and multivariate analyses showed that the expression of Shh, Gli1, and Cyr61 could predict the prognosis of patients (P < .05). Receiver operating characteristic curve analysis combined with TNM staging could better predict the three-year overall survival of patients (P < .05). Conclusion Shh, Gli1, and Cyr61 proteins are significantly expressed in gastric cancer tissues and are risk factors for the prognosis of patients with gastric cancer.

HPV16 infection promotes the malignant transformation of the esophagus and progression of esophageal squamous cell carcinoma

“…A total of 305 genes were upregulated by more than twofold, and 73 genes were downregulated by more than 1/2‐fold in EPC2 (E6ov) cells ( p < 0.05). Among these upregulated genes in EPC2 (E6ov) cells, shh, a gene causing tracheoesophageal fistula with esophageal atresia and its coding protein is a risk factor for the prognosis of patients with gastric cancer, 15 was the most dramatically upregulated gene, and its messenger RNA (mRNA) level increased to 876.45‐fold of that in the control group. ROS1, whose alteration may be a prognostic biomarker in cervical adenocarcinoma, 16 was the most dramatically downregulated gene, and its mRNA level decreased to 0.01‐fold of that in the control group.…”